Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport

Although high-density lipoprotein (HDL) cholesterol is inversely correlated with cardiovascular risk, an emerging paradigm is focused on increasing reverse cholesterol transport (RCT) and HDL function via apolipoprotein A1 (ApoA1). The objective of this study was to investigate the effect of ApoA1 (CSL112) infusion on HDL protein composition, cholesterol esterification rate (CER), and cholesterol efflux capacity (CEC) in patients treated after acute myocardial infarction. CSL112 reduced levels of apolipoproteins A2, B, C, and E and serum amyloids A1 and A4, whereas ApoA1, ApoM, and lecithin-cholesterol acyltransferase were significantly elevated. Increased CEC, plasma HDL cholesterol levels, CER, and CEC also were observed in CSL112-treated patients.

Authors

Institutions

Publication Details

Journal
JACC Basic to Translational Science
Published
2024-11-15
DOI
https://doi.org/10.1016/j.jacbts.2024.11.001
Citations
5
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
1.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport

Matthias Pelzing, Andreas Gille, Xiahui Tan, Alexey Navdaev et al.
5 citations
JACC Basic to Translational Science
Diabetes, Cardiovascular Risks, and Lipoproteins
1.79
article

Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport

Matthias Pelzing, Andreas Gille, Xiahui Tan, Alexey Navdaev, Kendra A. Young, Bronwyn A. Kingwell, Rasika A. Mathias, Svetlana A. Didichenko, Elena Velkoska, Danielle Duffy, Heidi L. Collins, Steven J. Adelman, Brandon Greene, C. Michael Gibson
article en
5 citations

Abstract

Although high-density lipoprotein (HDL) cholesterol is inversely correlated with cardiovascular risk, an emerging paradigm is focused on increasing reverse cholesterol transport (RCT) and HDL function via apolipoprotein A1 (ApoA1). The objective of this study was to investigate the effect of ApoA1 (CSL112) infusion on HDL protein composition, cholesterol esterification rate (CER), and cholesterol efflux capacity (CEC) in patients treated after acute myocardial infarction. CSL112 reduced levels of apolipoproteins A2, B, C, and E and serum amyloids A1 and A4, whereas ApoA1, ApoM, and lecithin-cholesterol acyltransferase were significantly elevated. Increased CEC, plasma HDL cholesterol levels, CER, and CEC also were observed in CSL112-treated patients.

JACC Basic to Translational ScienceVol. 10(4)
Pasadena City College (US), California Institute of Technology (US), Beth Israel Deaconess Medical Center (US), Behringwerke (Germany) (DE), CSL (United States) (US), The Institute of Addiction Medicine (US), BioStrategies (United States) (US), CSL (Australia) (AU), CSL (Switzerland) (CH)
Zero hunger
Openalex Percentile: Top 13%
Diabetes, Cardiovascular Risks, and Lipoproteins
1.79
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.